Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10363224 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(9 years from now) | |
US8652527 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(9 years from now) | |
US9555005 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(9 years from now) | |
US9101545 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(9 years from now) | |
US8889190 | UPSHER SMITH LABS | Extended-release topiramate capsules |
Mar, 2033
(9 years from now) |
Drugs and Companies using TOPIRAMATE ingredient
Market Authorisation Date: 11 March, 2014
Treatment: Treatment of seizures
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8440631 | UPSHER SMITH LABS | Compositions for drug administration |
May, 2026
(2 years from now) | |
US9283280 | UPSHER SMITH LABS | Compositions for drug administration |
May, 2026
(2 years from now) | |
US8268791 | UPSHER SMITH LABS | Alkylglycoside compositions for drug administration |
May, 2026
(2 years from now) | |
US11337962 | UPSHER SMITH LABS | Formulations comprising triptan compounds |
Jun, 2030
(6 years from now) | |
US10603305 | UPSHER SMITH LABS | Formulations comprising triptan compounds |
Jun, 2030
(6 years from now) | |
US9974770 | UPSHER SMITH LABS | Formulations comprising triptan compounds |
Jun, 2030
(6 years from now) | |
US9610280 | UPSHER SMITH LABS | Formulations comprising triptan compounds |
Jun, 2030
(6 years from now) | |
US9211282 | UPSHER SMITH LABS | Formulations comprising triptan compounds |
Jul, 2031
(7 years from now) |
Drugs and Companies using SUMATRIPTAN ingredient
Market Authorisation Date: 25 January, 2019
Treatment: Acute treatment of migraine
Dosage: SPRAY;NASAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9295675 | UPSHER SMITH LABS | Testosterone gel compositions and related methods |
Feb, 2034
(10 years from now) | |
US8785426 | UPSHER SMITH LABS | Testosterone gel compositions and related methods |
Feb, 2034
(10 years from now) | |
US9662340 | UPSHER SMITH LABS | Testosterone gel compositions and related methods |
Feb, 2034
(10 years from now) |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 04 June, 2014
Treatment: Method for transdermal delivery of testosterone
Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10537554 | UPSHER SMITH LABS | Pharmaceutical composition for treating migraine |
Jan, 2036
(12 years from now) | |
US11364224 | UPSHER SMITH LABS | Pharmaceutical composition for treating migraine |
Jan, 2036
(12 years from now) |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 28 January, 2016
Treatment: Treatment of migraine
Dosage: SOLUTION;SUBCUTANEOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic